{
    "2018-08-28": [
        [
            {
                "time": "",
                "original_text": "[增持评级]贝达药业(300558)半年报点评：业绩复合预期 研发即将步入收获期",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "半年报",
                        "业绩复合预期",
                        "研发",
                        "收获期"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业:凯美纳销量增长明显,费用增加拖累业绩",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "凯美纳",
                        "销量增长",
                        "费用增加",
                        "拖累业绩"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}